Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Xiaoyu Jiangzhi capsule is a Traditional Chinese Medicine (TCM) formulation primarily utilized in China for the management of hyperlipidemia and the prevention of atherosclerosis. The capsule is composed of multiple botanical extracts traditionally indicated to "remove blood stasis" and "lower lipids." Its pharmacological profile includes the modulation of lipid metabolism and the reduction of systemic inflammation. Clinical research, including Phase 4 trials sponsored by institutions such as Shanghai East Hospital, has focused on its application in chronic coronary syndrome (CCS). These studies evaluate the drug's impact on high-sensitivity C-reactive protein (hs-CRP) and other inflammatory and lipid markers, as well as its potential to reduce major adverse cardiovascular and cerebrovascular events (MACCE) and improve quality of life in adult patients.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Xiaoyu Jiangzhi capsule.